Argent's CannEpil™ Wins Approval for German Prescription Under Special Access Scheme
- StockSurge Team
- 5 days ago
- 2 min read
Argent BioPharma (ASX: RGT) has secured approval for its cannabinoid-based epilepsy treatment, CannEpil™, to be prescribed in Germany. The approval grants physicians the ability to prescribe CannEpil™ under a special access scheme, making it available to patients with refractory epilepsy, a condition with limited treatment options.
Germany represents a key pharmaceutical hub in Europe, and its regulatory framework potentially paves the way for broader acceptance of CannEpil™ across the EU.
With an estimated 816,000 epilepsy patients in Germany—many of whom suffer from drug-resistant forms—demand for innovative therapies remains high. The introduction of CannEpil™ provides an alternative for those who have not responded to traditional treatments, reinforcing the growing acceptance of cannabinoid-based medicine in managing central nervous system (CNS) disorders.
Strategic Growth in Neuroimmune Modulation
The approval of CannEpil™ strengthens Argent BioPharma’s position in neuroimmune modulation and cannabinoid therapeutics. The company has been expanding its footprint in CNS treatment, with a focus on leveraging cannabinoids to regulate immune response and inflammation in neurological diseases.
“The approval of CannEpil™ in Germany represents a significant milestone for Argent BioPharma and the patients who rely on innovative treatments for epilepsy." said Roby Zomer, Managing Director and CEO of Argent BioPharma. "This marks our continued expansion in Europe and reinforces our commitment to improving lives through cutting-edge cannabinoid-based medicine.”
The company plans to support the rollout by initiating physician education programs, expanding its German distribution network, and pursuing regulatory approvals in other EU nations.
Argent BioPharma continues to develop its broader pipeline, which includes cannabinoid-based treatments such as CogniCann® and CimetrA®. As the company scales its European presence, it is expected to capitalize on the rising demand for alternative CNS therapies.
